Last updated on February 2018

Efficacy and Safety of HPC-03 for Postmenopausal Symptom


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Postmenopause
  • Age: Between 40 - 60 Years
  • Gender: Female

Inclusion Criteria:

  1. Women 40 to 60 years old who have passed one year or more since the last menstrual period
  2. Women with a kupperman index score of 20 or higher
  3. Women who have agreed to participate in this trial before the start of the clinical trial and who have written an informed consent

Exclusion Criteria:

  1. Women with a body mass index (BMI) greater than 30 kg / m2
  2. Women using hormone preparations such as female hormones or similar hormone preparations (plant extracts, etc.) within 3 months
  3. Women with a history of endometrial hyperplasia, uterine cancer, endometrial cancer, breast or breast disease, sex hormone related cancer
  4. A woman with a history of severe migraine within the past 1 year, diagnosed with thromboembolism, cerebrovascular disease, myocardial infarction, unstable angina, or coronary angioplasty
  5. Women with severe mental illnesses such as depression and anxiety disorder, or those currently taking psychotropic drugs such as antidepressants
  6. Women with irregular uterine bleeding after 1 year of menopause
  7. Patients with uncontrolled hypertension (160 / 100mmHg or higher, after 10 minutes of clinical test subjects)
  8. Patients with diabetes whose blood sugar is not controlled (fasting glucose 180 mg / dL or diabetes mellitus within 3 months)
  9. Those with uncontrolled thyroid disease (those who are considered to be able to participate in this trial by the tester can participate)
  10. drug or alcohol abuser
  11. If ALT(Alanine transaminase ) or AST(Aspartate transaminase) exceeds 3 times the normal upper limit of the research institute
  12. If creatinine exceeds twice the upper limit of the normal level of research institute
  13. Mammography / PAP smear If a clinically significant abnormality (Breast imaging-reporting and data system: BI-RADS category 0 or 3 or more, PAP smear is not abnormal up to ASCUS:atypical cells of undetermined significance) is confirmed (BI-RADS Category 0, )
  14. If you have participated in another clinical trial within one month of the start of this trial or plan to participate in another clinical trial during the trial period
  15. If the tester judges that the test is inappropriate for this clinical trial
  16. Women using thyroid hormone preparations, clonidine, anticoagulants or antithrombotic agents (Warfarin, Clopidogrel, etc.) within 3 months
  17. Women who took medicines or health functional foods related to women's menopause within a month

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.